# Calypso Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/calypso-biotech

- Industry: Biotechnology
- Headquarters: Plan-les-Ouates, Switzerland
- Total disclosed funding: $35M
- Latest round: Series A (Sep 9, 2021)
- Investors on record: 5

## About

Based in Switzerland and founded in 2013 by co-founders Alain Vicari Ph.D. and Yolande Chvatchko Ph.D., Calypso Biotech BV operates as a provider of monoclonal antibodies for treating immune-related diseases to healthcare providers and medical researchers. In January 2024, Novartis International AG agreed to acquire Calypso Biotech BV from Gilde Healthcare Partners, Merck Ventures, Inkef, Johnson & Johnson Innovation, and Fountain Healthcare Partners for USD 250 million, including an additional USD 175 million on achievement of certain milestones.

The company provides a wide range of biotech products, such as therapeutic antibodies like CALY-002 for treating conditions such as celiac disease and eosinophilic esophagitis. CALY-002 is a clinical-stage antibody that neutralizes interleukin-15, targeting immune pathologies with large unmet medical needs. Additionally, the firm also provides preclinical studies and drug development services.

## Funding rounds

- Series A, Sep 9, 2021, $9.5M — Gilde Healthcare, Johnson & Johnson Innovation, Fountain Healthcare Partners, M Ventures, Inkef
- Series A, Feb 20, 2019, $23M — Gilde Healthcare, Johnson & Johnson Innovation, M Ventures, Inkef
- Seed, Mar 4, 2013, $3.3M — M Ventures

## Investors

- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Seed, Series A
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- Inkef (https://capitalatlas.ai/funds/inkef) — Series A
- Fountain Healthcare Partners (https://capitalatlas.ai/funds/fountain-healthcare-partners) — Series A